Index · Artikel · Pfizer's Lyrica shows no relief from post-traumatic nerve pain

Pfizer's Lyrica shows no relief from post-traumatic nerve pain

2015-11-25 0
   
Advertisement
résumén">Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study. The drug did not lead to pain reduction in patients compared with a placebo, th
Advertisement

Pfizer's Lyrica shows no relief from post-traumatic nerve pain


n">Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study.

The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday.

Currently, there is no approved treatment in the United States for post-traumatic neuropathic pain.

Lyrica, which generated $1.22 billion in sales in the third quarter, is already approved to treat nerve pain associated with diabetes, shingles, spinal cord injury and fibromyalgia.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated